What's new

[PIO] EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age

31103.jpg




The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of Comirnaty and Spikevax vaccines against the original SARS-CoV-2 virus strain. The Committee recommended the inclusion of the use of Comirnaty vaccine in children aged 6 months to 4 years and the use of Spikevax vaccine in children aged 6 months to 5 years. Comirnaty and Spikevax vaccines are already authorised for use in both adults and children aged 5 and 6 years, respectively.

Compared to the dosage for the already authorised age groups, the doses of both vaccines in these new younger age groups will be lower. In children aged 6 months to 4 years, Comirnaty may be administered as an initial vaccination regimen consisting of three doses (3 micrograms each dose). The first two doses shall be administered three weeks apart, followed by a third dose administered at least 8 weeks after the second dose. In children from 6 months to 5 years of age, Spikevax may be administered as an initial vaccination regimen consisting of two doses (25 micrograms per dose), spaced four weeks apart. For children in these age groups, both vaccines are administered as intramuscular injections into the muscles of the upper arm or thigh.

Regarding Comirnaty, a main study in children aged 6 months to 4 years showed that the immune response to the lowest dose of Comirnaty (3 micrograms) was comparable to that observed with the highest dose (30 micrograms) in subjects aged 16 to 25 years. For Spikevax, a pivotal study in children aged 6 months to 5 years showed that the immune response to the lowest dose of Spikevax (25 micrograms) was comparable to that observed with the highest dose (100 micrograms) in subjects aged 18 to 25 years. Both studies evaluated the immune response induced by the administration of the vaccines by measuring the level of antibodies against SARS-CoV-2 virus.

The most common adverse events for both vaccines, in children aged 6 months to 4 or 5 years, were comparable to those observed in older age groups. With Comirnaty, irritability, drowsiness, loss of appetite, rash and injection site tenderness were also common adverse reactions in children aged 6 to 23 months, whereas with Spikevax, irritability, crying, loss of appetite and drowsiness were common adverse reactions in children aged 6 to 36 months. For both vaccines, these effects were usually mild or moderate and improved within a few days of vaccination.

The CHMP therefore concluded that the benefits of Comirnaty and Spikevax vaccines in children aged 6 months to 4 and 5 years, respectively, outweigh the risks.

The safety and efficacy of both vaccines, in children and adults, will continue to be closely monitored as they are used in vaccination campaigns in EU Member States through the EU pharmacovigilance system and ongoing and additional studies conducted by the company and coordinated by the European authorities.

The original authorised vaccines, Comirnaty and Spikevax, are both effective in preventing serious disease, hospitalisation and death associated with COVID-19 and continue to be used as part of vaccination campaigns in the EU, particularly for initial vaccination schedules. National authorities in EU Member States will determine who is recommended to be vaccinated and when, taking into account factors such as infection and hospitalisation rates, risk to vulnerable groups, vaccination coverage and availability of vaccines.

The CHMP recommendations will now be sent to the European Commission, which will issue final decisions applicable to all EU Member States.

How the vaccines work

Both vaccines work by preparing the body to defend itself against COVID-19. Each vaccine contains a molecule called messenger RNA (mRNA) that has instructions for making the spike protein. This is a protein on the surface of the SARS-CoV-2 virus that the virus needs to enter the body's cells.

When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike protein. The person's immune system will then recognise this protein as foreign and produce antibodies and activate T-cells (white blood cells) to attack it.

If, later, the vaccinated person comes into contact with the SARS-CoV-2 virus, the immune system will recognise it and be ready to defend the body against it. The mRNA molecules from the vaccines do not remain in the body but are broken down shortly after vaccination.

Where to find more information

The product information approved by CHMP for Comirnaty and Spikevax contains prescribing information for healthcare professionals and an instruction sheet for the public.

Evaluation reports, detailing the EMA's assessments of the use of Comirnaty and Spikevax in children from 6 months of age, will be published on the EMA website.

Studies in children were conducted in accordance with the paediatric investigation plan (PIP) for each vaccine, agreed by the EMA Paediatric Development Committee (PDCO). Clinical trial data submitted by companies in their applications for paediatric indication extensions will be published on the Agency's clinical data website in due course.

More information is available in the common language summaries of the vaccines, including a description of the benefits and risks of each vaccine and why EMA recommended their approval in the EU.

Safety monitoring

According to the EU safety monitoring plan for COVID-19 vaccines, Comirnaty and Spikevax vaccines are closely monitored and subject to several activities specific to COVID-19 vaccines. Independent studies on COVID-19 vaccines coordinated by the EU authorities will provide more information on the long-term safety and benefits of the vaccines in the general population.

These measures will allow regulators to rapidly assess data emerging from a range of different sources and take appropriate regulatory action to protect public health, if necessary.

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

[/P]
 
Back
Top